Agios Pharmaceuticals Inc (NASDAQ:AGIO) has received an average recommendation of “Buy” from the fourteen research firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $80.22.
Several brokerages have issued reports on AGIO. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, January 15th. Royal Bank of Canada boosted their target price on Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a research note on Thursday, January 18th. They noted that the move was a valuation call. BidaskClub upgraded Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Finally, Credit Suisse Group boosted their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd.
In related news, insider Steven L. Hoerter sold 25,000 shares of the business’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $74.83, for a total transaction of $1,870,750.00. Following the sale, the insider now directly owns 25,000 shares in the company, valued at approximately $1,870,750. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Corp /De/ Celgene acquired 851,154 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were bought at an average price of $67.00 per share, for a total transaction of $57,027,318.00. Following the completion of the purchase, the insider now owns 1,374,599 shares in the company, valued at approximately $92,098,133. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 187,114 shares of company stock worth $14,109,545. 5.43% of the stock is currently owned by corporate insiders.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down $3.07 on Friday, hitting $71.19. The company’s stock had a trading volume of 129,268 shares, compared to its average volume of 843,209. The company has a market capitalization of $3,620.00, a price-to-earnings ratio of -11.44 and a beta of 2.12. Agios Pharmaceuticals has a 52-week low of $45.11 and a 52-week high of $82.96.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.